Antonio J Grillo-López

Author

Also Known As

A Grillo-Lopez, A Grillo-López, A J Grillo-López, Antonio Grillo-Lopez, Antonio Grillo-López, Antonio J Grillo-López, Antonio J. Grillo-Lopez, Antonio J. Grillo-López, Antonio J. Grillo-López, Antonio J. Grillo‐López

Publications

11.5K

Citations

H-Index

Concepts

All Affiliations

Fox Chase Cancer Center Biogen (Switzerland)Northwestern University Robert H. Lurie Comprehensive Cancer Center of Northwestern University Mayo Clinic in Arizona

About

Antonio J Grillo-López is an author at Fox Chase Cancer Center specializing in medicine, pathology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.3K
2	Immunology	5	5	499
3	Health Sciences	2	2	84
4	Allergy	1	1	30
5	Head And Neck Surgery	1	1	43

Antonio J Grillo-López

Publications

7.5K

Citations

H-Index

Page 1

	Year	Citations
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma David G. Maloney, Antonio J Grillo-López, Christine A. White, Blood	1997	1.7K
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas, Journal of Clinical Oncology	2002	1.2K
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment Thomas A. Davis, Antonio J Grillo-López, Christine A. White, Journal of Clinical Oncology	2000	688
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20<sup>+</sup>B-Cell Non-Hodgkin's Lymphoma Thomas E. Witzig, Christine A. White, Gregory A. Wiseman, Journal of Clinical Oncology	1999	538
Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity John C. Byrd, Timothy J. Murphy, Robin Howard, Journal of Clinical Oncology	2001	511
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment James L. Rubenstein, Dan Combs, J. Rosenberg, Blood	2002	419
Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up Myron S. Czuczman, Robin Weaver, Baha Alkuzweny, Journal of Clinical Oncology	2004	364
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Susan J. Knox, Michael L. Goris, Kirk Trisler, PubMed Hematological MalignancyLymphoid NeoplasiaMedicineMalignant Blood DisorderHematology	1996	332
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Blood	2002	266
Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Gregory A. Wiseman, Christine A. White, Michael Stabin, European Journal of Nuclear Medicine and Molecular Imaging Lymphoid NeoplasiaRadioimmunotherapy Dosimetry ResultsPhase I/ii 90MedicineYttrium-90 Ibritumomab Tiuxetan	2000	234

Page 1